From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Ensifentrine dose | TDI focal score | SGRQ-C total score | ||
---|---|---|---|---|
Mean (SD) | Treatment–placebo difference (95% confidence interval); p value | Mean (SD) | Treatment–placebo difference (95% confidence interval); p value | |
6 mg (N = 80) | 1.39 (2.179) | 1.11 (0.16 to 2.06); 0.022 | 41.5 (15.20) | −2.67 (− 6.26 to 0.91); 0.143 |
3 mg (N = 82) | 1.55 (3.436) | 1.19 (0.25 to 2.14); 0.014 | 40.1 (15.93) | −2.29 (−5.96 to 1.37); 0.220 |
1.5 mg (N = 81) | 1.92 (3.221) | 1.64 (0.69 to 2.59); 0.001 | 41.4 (16.24) | −2.85 (−6.46 to 0.76); 0.121 |
0.75 mg (N = 81) | 1.49 (2.810) | 1.29 (0.32 to 2.25); 0.009 | 45.1 (14.95) | −2.22 (−5.87 to 1.42); 0.231 |
Placebo (N = 79) | 0.37 (3.220) | 43.5 (16.99) |